KR102474196B1 - Functional oral composition containing glutamine to relieve dentin hypersensitivity - Google Patents
Functional oral composition containing glutamine to relieve dentin hypersensitivity Download PDFInfo
- Publication number
- KR102474196B1 KR102474196B1 KR1020220083734A KR20220083734A KR102474196B1 KR 102474196 B1 KR102474196 B1 KR 102474196B1 KR 1020220083734 A KR1020220083734 A KR 1020220083734A KR 20220083734 A KR20220083734 A KR 20220083734A KR 102474196 B1 KR102474196 B1 KR 102474196B1
- Authority
- KR
- South Korea
- Prior art keywords
- glutamine
- oral composition
- dentin
- calcium carbonate
- dentinal tubules
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 201000002170 dentin sensitivity Diseases 0.000 title description 11
- 239000000606 toothpaste Substances 0.000 claims abstract description 22
- 229940034610 toothpaste Drugs 0.000 claims abstract description 21
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 39
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 36
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 32
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 19
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 16
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000013355 food flavoring agent Nutrition 0.000 claims description 7
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003002 pH adjusting agent Substances 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 239000000080 wetting agent Substances 0.000 claims description 5
- 210000005239 tubule Anatomy 0.000 abstract description 33
- 210000004268 dentin Anatomy 0.000 abstract description 29
- 208000024891 symptom Diseases 0.000 abstract description 20
- 150000001413 amino acids Chemical class 0.000 abstract description 6
- 230000033558 biomineral tissue development Effects 0.000 abstract description 2
- 230000008595 infiltration Effects 0.000 abstract 1
- 238000001764 infiltration Methods 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 25
- 230000000694 effects Effects 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 5
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 229940091249 fluoride supplement Drugs 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 229910001414 potassium ion Inorganic materials 0.000 description 4
- 235000010333 potassium nitrate Nutrition 0.000 description 4
- 239000004323 potassium nitrate Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 239000000120 Artificial Saliva Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 3
- 235000019204 saccharin Nutrition 0.000 description 3
- 229940081974 saccharin Drugs 0.000 description 3
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 3
- 208000004371 toothache Diseases 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical class OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 2
- 229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241001674048 Phthiraptera Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 210000003074 dental pulp Anatomy 0.000 description 2
- 239000000551 dentifrice Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ZZPQSQFQHIGCRC-OOFFSTKBSA-N (2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-c Chemical compound [Zn].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ZZPQSQFQHIGCRC-OOFFSTKBSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229940090898 Desensitizer Drugs 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 208000036372 Sensitivity of teeth Diseases 0.000 description 1
- ITJLNEXJUADEMK-UHFFFAOYSA-N Shirin Natural products CCC(C)(O)c1c(Cl)c(OC)c(C)c2OC(=O)c3c(C)c(Cl)c(O)c(Cl)c3Oc12 ITJLNEXJUADEMK-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 235000021270 cold food Nutrition 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000005562 gingival recession Diseases 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- GBCAVSYHPPARHX-UHFFFAOYSA-M n'-cyclohexyl-n-[2-(4-methylmorpholin-4-ium-4-yl)ethyl]methanediimine;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1CCCCC1N=C=NCC[N+]1(C)CCOCC1 GBCAVSYHPPARHX-UHFFFAOYSA-M 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000004416 odontoblast Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- -1 phloxamer Chemical compound 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000031070 response to heat Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 230000036410 touch Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 글루타민을 포함하는 시린 이 증상 완화 기능성 구강용 조성물에 관한 것으로서, 더욱 구체적으로 상아관 내 체액 흐름 변경(Dentinal Tubule Occlusion)을 통한 시린 이 증상 완화 기능을 갖는 구강용 조성물에 관한 것이다.The present invention relates to a functional oral composition for relieving cold tooth symptoms containing glutamine, and more particularly, to an oral composition having a function for relieving cold tooth symptoms through alteration of bodily fluid flow in the dentinal tube (Dentinal Tubule Occlusion).
여기서는, 본 개시에 관한 배경기술이 제공되며, 이들이 반드시 공지기술을 의미하는 것은 아니다.BACKGROUND OF THE INVENTION Here, background art related to the present disclosure is provided, and they are not necessarily meant to be prior art.
시린 이 증상 (상아질 과민증, Dentin Hypersensitivity; DH)은 법랑질로 쌓여 있는 치아표면이 열, 증발, 촉각, 삼투 또는 화학적 자극에 대한 반응으로 마모되거나 깨져 상아세관이 노출되고 외부 자극에 취약해져 외부환경에 아주 민감한 치아가 되는 증상으로 노출된 상아질에서 발생하는 짧고 날카로운 통증으로 정의된다.Toothache (Dentin Hypersensitivity; DH) is when the tooth surface, which is covered with enamel, wears out or cracks in response to heat, evaporation, touch, osmosis, or chemical stimulation, exposing the dentinal tubules and becoming vulnerable to external stimuli to the external environment. It is defined as a brief, sharp pain that occurs in exposed dentin as a symptom of very sensitive teeth.
2010년에 수행된 광범위한 7개 유럽 국가의 젊은 성인 3500여명의 임상 조사와 자가 보고 설문지를 토대로 상아질 과민증 유병률이 평가되었다. 유럽의 젊은 성인 중 최대 42%가 시린 이 증상의 영향을 받는다는 결과가 보고되었다. (선행기술문헌; 비특허문헌 1)또한 국내에서도 2019년 기준 성인 3명 중 2명이 앓는 것으로 조사되는 만큼 흔히 발생하는 구강 건강 문제이다.In 2010, the prevalence of dentin hypersensitivity was assessed based on a clinical survey and self-report questionnaire of over 3500 young adults from a wide range of seven European countries. Results have reported that up to 42% of young adults in Europe are affected by this condition. (Prior art literature; Non-Patent Document 1) It is also a common oral health problem in Korea, as it is investigated that 2 out of 3 adults suffer from it as of 2019.
가장 널리 받아들여지는 통증 이론은 Gysi(선행기술문헌; 비특허문헌 2)에 의해 처음 제안되었고 이후 Brㅴnnstrㆆm(선행기술문헌; 비특허문헌 3-5)에 의해 입증된 유체역학 이론이다. 이것은 민감한 상아질이 상아세관의 자극 유발 유체 흐름과 치수/상아질 경계 영역에서의 결과적인 통각수용기 활성화에 기반한다는 이론을 뒷받침한다. The most widely accepted pain theory is the hydrodynamic theory first proposed by Gysi (prior art document; non-patent document 2) and later proven by Brønnström (prior art document; non-patent document 3-5). . This supports the theory that sensitive dentin is based on stimulation-induced fluid flow in the dentinal tubules and consequent nociceptor activation in the pulp/dentin interface region.
인체 연구에 따르면 상아세관의 개통(patency)은 시린 이 증상의 중요한 특성이며, 상아세관의 밀도와 노출된 치경부의 상아질 표면에서 유도되는 통증 반응 사이에 상당한 양의 상관관계가 있음을 보여준다. 발치된 치아에 대한 추가 연구는 민감하지 않은 치아와 비교하여 민감한 치아가 협측 (buccal) 치경부 (cervical) 상아질 부위에 8 배 더 많고 두배 더 넓은 세관을 갖는 가지고 있다는 강력한 과학적 근거를 제시하였다. (선행기술문헌; 비특허문헌 6) (도 1 및 도 2 참고).Human studies have shown that dentinal tubular patency is an important characteristic of apnea, and that there is a significant positive correlation between dentinal tubule density and the pain response elicited from the exposed cervical dentin surface. Further studies of extracted teeth provided strong scientific evidence that, compared to unsensitized teeth, sensitive teeth had eight times more and twice as wide tubules in the buccal and cervical dentin regions. (Prior art document; non-patent document 6) (see FIGS. 1 and 2).
시린 이 증상이 발생하려면 치아의 상아질 표면이 노출(Lesion localisation) 되어야 하는데, 이는 치경부의 법랑질 마모 또는 치은 퇴축에 의해 일어난다. 그 다음 서로 근접한 많은 상아세관의 개통, 상아세관이 치수에서 구강 환경으로 열리거나 개방(Lesion initiation)되어야 하며, 일반적으로 산성 식품 또는 음료에 의해 일어난다.Cold The dentin surface of the tooth must be exposed (lesion localization) for this symptom to occur, which is caused by cervical enamel abrasion or gingival recession. Then opening of many dentinal tubules in close proximity to one another, the opening or opening of the dentinal tubules from the pulp to the oral environment (Lesion initiation), usually caused by acidic foods or beverages.
우리가 매일 사용하는 치약은 시린 이 증상(상아질 과민증) 치료에 사용되는 가장 일반적인 제제이며 국내 상아질 과민증용으로 판매되는 대부분의 치약은 치수신경 반응(Pulpal Nerve Response)을 조절하거나 차단하는 것을 목적으로 하고 있다. 칼륨 이온과 같은 탈 감작제는 세뇨관을 따라 확산되고 치수 주변의 칼륨 이온 농도를 증가시켜 치수내 신경 흥분성을 감소시켜 치수내 신경 기능을 억제 또는 차단할 수 있다. (선행기술문헌; 비특허문헌 7) The toothpaste we use every day is the most common agent used to treat cold tooth symptoms (dentin hypersensitivity), and most of the toothpastes sold for dentin hypersensitivity in Korea aim to control or block the pulpal nerve response (Pulpal Nerve Response). have. Desensitizers, such as potassium ions, can diffuse along the tubules and increase the potassium ion concentration around the pulp, thereby reducing nerve excitability in the pulp, thereby inhibiting or blocking nerve function in the pulp. (Prior art literature; non-patent literature 7)
하지만 최근 발표된 칼륨 이온이 상아질 과민증 치료에 미치는 효능에 대한 체계적 문헌고찰 (systematic review)에서 칼륨 이온이 가지고 있는 약효의 증거는 약하거나 또는 불충분하다고 보고되었다. (선행기술문헌; 비특허문헌 8)However, in a recently published systematic review of the efficacy of potassium ions in the treatment of dentin hypersensitivity, it was reported that the evidence of the efficacy of potassium ions was weak or insufficient. (Prior art literature; non-patent literature 8)
상아질 과민증에 의한 통증완화에 가장 직접적인 방법은 치수에서 구강환경으로 이어지는 상아세관의 폐쇄(Dentinal Tubule Occlusion) 이다. 상아세관을 막거나 직경을 줄여 체액의 이동을 억제하면 신경 자극을 줄일 수 있다. The most direct way to relieve pain caused by dentin hypersensitivity is occlusion of the dentinal tubules leading from the dental pulp to the oral environment. Nerve stimulation can be reduced by blocking or reducing the diameter of the dentinal tubules to inhibit fluid movement.
종래에는 치약 조성물에 포함된 인산삼칼슘이 펩타이드와 결합하여 상아세관 및 상아질 표면에 재광화(remineralisation)를 유도하고, 펩타이드에 의한 상아모세포 분화촉진으로 치수/치수강 내에서의 상아질의 재생을 촉진시키는 연구가 수행되었다. (선행기술문헌, 특허문헌 1) 하지만 도 3에 나타낸 것과 같이 상아질 모세포는 치수강 내부 표층에 규칙적으로 배열되어 있으며 상아질을 형성하는 세포이기 때문에 특허문헌 1과 같이 펩타이드(아미노산이 2개 이상 결합)를 통한 상아질의 재생촉진은 상아질 모세포가 자리하는 치수/치수강 내에서만 이루어 질 수 있어 시린 이 증상 완화에 오랜 시간이 필요하며, 칫솔질 방법에 따라 효과가 미미할 수 있다.Conventionally, tricalcium phosphate included in toothpaste compositions binds to peptides to induce remineralization on the surface of dentinal tubules and dentin, and promotes dentin regeneration in the dental pulp / pulp cavity by promoting differentiation of odontoblasts by the peptides. A study was conducted. (Prior art literature, Patent Document 1) However, as shown in Figure 3, dentin blast cells are regularly arranged on the surface layer inside the pulp cavity and are cells that form dentin, so as in Patent Document 1, peptides (two or more amino acids bonded) The promotion of dentin regeneration through the toothbrush can only be done within the pulp/pulp cavity where the dentin hair cells are located, so it takes a long time to relieve the symptoms of cold teeth, and the effect may be insignificant depending on the brushing method.
본 발명은 상아세관의 폐쇄 방법을 통해 시린 이 증상을 효과적으로 완화할수 있는 구강용 조성물을 제공하고자 한다. The present invention is to provide an oral composition that can effectively alleviate the symptoms of cold teeth through the method of closing the dentinal tubules.
그러나 본 발명의 목적들은 상기에 언급된 목적으로 제한되지 않으며, 언급되지 않은 또 다른 목적들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.However, the objects of the present invention are not limited to the above-mentioned objects, and other objects not mentioned will be clearly understood by those skilled in the art from the description below.
본 발명은 글루타민(Glutamine)을 5 내지 10 wt% 포함하는 것을 특징으로 하는 구강용 조성물을 제공한다. The present invention provides an oral composition comprising 5 to 10 wt% of glutamine (Glutamine).
또한 본 발명은 글루타민(Glutamine), 탄산수소나트륨(sodium hydrogen carbonate) 및 탄산칼슘(calcium carbonate)을 포함하는 기능성 성분을 포함하는 것을 특징으로 하는 구강용 조성물을 제공한다. In addition, the present invention provides an oral composition comprising functional ingredients including glutamine (Glutamine), sodium hydrogen carbonate (sodium hydrogen carbonate) and calcium carbonate (calcium carbonate).
또한 상기 기능성 성분은 22.5 내지 35 중량% 포함되고, 상기 기능성 성분 내에서 탄산수소나트륨 및 탄산칼슘 각각의 함량이 글루타민의 함량과 같거나 높은 것을 특징으로 한다.In addition, the functional component is included in 22.5 to 35% by weight, and the content of sodium bicarbonate and calcium carbonate in the functional component is equal to or higher than that of glutamine.
또한 상기 기능성 성분 내에서 글루타민 : 탄산수소나트륨 : 탄산칼슘의 혼합 비율은 1 : 1.5~2 : 1~1.5 인 것을 특징으로 한다.In addition, the mixing ratio of glutamine: sodium hydrogen carbonate: calcium carbonate in the functional component is characterized in that 1: 1.5 ~ 2: 1 ~ 1.5.
또한 상기 구강용 조성물은 습윤제, 점도조절제, 계면활성제, 불소제, pH 조절제, 방부제 및 향미제로 구성되는 군에서 선택되는 1종 이상을 더 포함하는 치약 조성물인 것을 특징으로 한다.In addition, the oral composition is characterized in that the toothpaste composition further comprises at least one member selected from the group consisting of a wetting agent, a viscosity modifier, a surfactant, a fluorine agent, a pH modifier, a preservative and a flavoring agent.
본 발명은 독자적인 아미노산을 이용하여 상아질 및 상아세관과 화학적으로 유사한 플러그(plug)를 견고하게 형성하며, 치아 밖 및 상아질 표면으로부터의 상아세관 침투, 봉쇄 및 광화(mineralization)를 통해 시린 이 증상을 효과적으로 완화할 수 있는 구강용 조성물을 제공하는 것이다.The present invention firmly forms a plug chemically similar to dentin and dentinal tubules using a unique amino acid, and effectively treats cold tooth symptoms through penetration, blockade, and mineralization of dentinal tubules from the outside of the tooth and from the dentin surface. It is to provide a composition for oral cavity that can be alleviated.
도 1은 5000배 확대 전자현미경 이미지로써 노출된, 시린 이의 상아세관을 보여주는 예이다.
도 2는 5000배 확대 전자현미경 이미지로써 노출되지 않은, 시리지 않은 이의 상아세관을 보여주는 예이다.
도 3은 치아의 구조를 나타내는 이미지이다.
도 4는 실시예 및 비교예에 따른 치약 조성물 처리 후 전자현미경 이미지이다.1 is an example showing dentinal tubules of a cold tooth exposed as an electron microscope image at 5000x magnification.
FIG. 2 is an example showing unexposed and unstained dentinal tubules as an electron microscope image magnified 5000 times.
3 is an image showing the structure of a tooth.
Figure 4 is an electron microscope image after treatment with toothpaste compositions according to Examples and Comparative Examples.
본 명세서에 사용되는 모든 기술용어 및 과학용어는 다른 언급이 없는 한은 기술적으로 통상의 기술을 가진 자에게 일반적으로 이해되는 것과 동일한 의미를 가진다. 또한 본 명세서 및 청구범위의 전반에 걸쳐, 다른 언급이 없는 한 포함(comprise, comprises, comprising)이라는 용어는 언급된 물건, 단계 또는 일군의 물건, 및 단계를 포함하는 것을 의미하고, 임의의 어떤 다른 물건, 단계 또는 일군의 물건 또는 일군의 단계를 배제하는 의미로 사용된 것은 아니다.All technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art unless otherwise specified. Also throughout this specification and claims, the terms "comprise", "comprising", and "comprising", unless stated otherwise, are meant to include a stated object, step or group of objects, and steps, and any other It is not intended to exclude an object, step or group of objects or steps.
이하에 본 발명을 상세하게 설명하기에 앞서, 본 명세서에 사용된 용어는 특정의 실시예를 기술하기 위한 것일 뿐 첨부하는 특허청구의 범위에 의해서만 한정되는 본 발명의 범위를 한정하려는 것은 아님을 이해하여야 한다.Prior to describing the present invention in detail below, it is understood that the terms used herein are intended to describe specific embodiments and are not intended to limit the scope of the present invention, which is limited only by the appended claims. shall.
한편, 본 발명의 여러 가지 실시예들은 명확한 반대의 지적이 없는 한 그 외의 어떤 다른 실시예들과 결합될 수 있다. 특히 바람직하거나 유리하다고 지시하는 어떤 특징도 바람직하거나 유리하다고 지시한 그 외의 어떤 특징 및 특징들과 결합될 수 있다. 이하, 첨부된 도면을 참조하여 본 발명의 실시예 및 이에 따른 효과를 설명하기로 한다.On the other hand, various embodiments of the present invention can be combined with any other embodiments unless clearly indicated to the contrary. Any feature indicated as being particularly desirable or advantageous may be combined with any other features and characteristics indicated as being particularly desirable or advantageous. Hereinafter, embodiments of the present invention and effects thereof will be described with reference to the accompanying drawings.
본 발명의 일실시예에 따른 구강용 조성물은 글루타민(Glutamine), 탄산수소나트륨(sodium hydrogen carbonate) 및 탄산칼슘(calcium carbonate)을 포함하는 기능성 성분을 포함하여 고용해성인 글루타민과 탄산수소나트륨의 화합물(Glutamine Bicarbonate)이 불용성인 탄산칼슘 입자에 물리적으로 둘러싸이면서 접착 특성을 갖는 페이스트형 플러그 화합물을 형성한다. 이 페이스트형 플러그 화합물은 상아세관 내벽에 침투 및 부착되어 상아세관을 봉쇄함으로써 시린 이 증상을 빠르고 직접적으로 완화시킨다. 또한 알칼리성인 페이스트형 플러그 화합물은 상아세관 봉쇄 후 타액(침) 및 상아세관 내 액체(dentine tubule fluid)의 칼슘 및 인산염 이온과 반응하여 상아질 및 상아세관과 화학적으로 유사한 플러그를 형성함으로써 시간 경과에 따라 더욱 견고하게 상아세관을 폐쇄함으로써 시린 이 증상을 더욱 완화시킬 수 있다. 여기서 화학적으로 유사한 이유는 탄산칼슘이 전구물질 (precursor)로써 '하이드록시아파타이트' (Hydroxyapatite (HAp, Ca10(PO4)6(OH)2))를 형성하기 때문이다. 이때 중요한 역할을 하는 것이 필수 아미노산인 글루타민이다.An oral composition according to an embodiment of the present invention includes a functional component including glutamine, sodium hydrogen carbonate and calcium carbonate, a highly soluble compound of glutamine and sodium hydrogen carbonate ( Glutamine Bicarbonate) is physically surrounded by insoluble calcium carbonate particles to form a paste-type plug compound having adhesive properties. This paste-type plug compound penetrates and adheres to the inner wall of the dentinal tubules to block them, thereby providing rapid and direct relief from the symptoms of cold teeth. In addition, the alkaline paste-type plug compound reacts with calcium and phosphate ions in saliva (saliva) and dentine tubule fluid after sealing the dentinal tubules to form a plug chemically similar to dentin and dentinal tubules, thereby changing over time. By more firmly occluding the dentinal tubules, the symptoms of cold lice can be further alleviated. The chemically similar reason here is that calcium carbonate forms 'hydroxyapatite' (Hydroxyapatite (HAp, Ca 10 (PO 4 ) 6 (OH) 2 )) as a precursor. At this time, glutamine, an essential amino acid, plays an important role.
상기 구강용 조성물에 포함되는 글루타민(glutamine)은 화학식 C5H10N2O3 의 중성 아미노산으로 물에 녹는다. 더욱 구체적으로 탄산칼슘이 하이드록시아파타이트로 변형되는데 필수적인 Glutamine Bicarbonate의 생성을 원활하게 하기 위해 Laevorotatory 형태의 글루타민(L-Glutamine)을 사용하는 것이 좋다.Glutamine included in the oral composition is a neutral amino acid having the formula C 5 H 10 N 2 O 3 and is soluble in water. More specifically, it is good to use Laevorotatory form of glutamine (L-Glutamine) to facilitate the production of Glutamine Bicarbonate, which is essential for calcium carbonate to be transformed into hydroxyapatite.
상기 구강용 조성물에 상기 글루타민, 탄산수소나트륨 및 탄산칼슘을 포함하는 기능성 성분은 22.5 내지 35 중량% 포함되고, 이때 기능성 성분 내에서 탄산수소나트륨과 탄산칼슘 각각의 함량은 글루타민의 함량과 같거나 높아야 하며, 더욱 구체적으로는 글루타민 : 탄산수소나트륨 : 탄산칼슘의 혼합 비율은 1 : 1.5~2 : 1~1.5 이다. 바람직하게는 기능성 성분은 30 내지 35 중량% 포함되고, 이때 글루타민 : 탄산수소나트륨 : 탄산칼슘의 혼합 비율이 1 : 1.5~1.8 : 1~1.2인 것이 좋다. The oral composition contains 22.5 to 35% by weight of the functional component including glutamine, sodium bicarbonate and calcium carbonate, wherein the content of sodium bicarbonate and calcium carbonate in the functional component is equal to or higher than that of glutamine. And, more specifically, the mixing ratio of glutamine: sodium bicarbonate: calcium carbonate is 1: 1.5 to 2: 1 to 1.5. Preferably, the functional component is included in an amount of 30 to 35% by weight, and in this case, the mixing ratio of glutamine: sodium hydrogen carbonate: calcium carbonate is preferably 1: 1.5 to 1.8: 1 to 1.2.
본 발명에 따른 구강용 조성물은 펩타이드 및 인산삼칼슘 등을 포함하여 상아질 표면에 얇은 막을 형성하고 재광화(remineralization)를 유도하는 특허문헌 1과 달리, 페이스트형 플러그 화합물이 상아세관 내에 직접 침투하여 플러그를 형성함으로써 봉쇄하는 것을 일 특징으로 한다. 본원발명은 별도의 인산 성분을 포함하지 않더라도 타액(침) 및 상아세관 내 액체에 이미 포함되어 있는 칼슘이온과 인산염 이온이 상기 페이스트형 플러그 화합물과 반응하여 광화(mineralization)되어 플러그(마개)를 형성하는 차이가 있다. 이는 사용자의 상아질 및 상아세관과 화학적으로 유사한 플러그를 형성하므로 더욱 견고하게 상아세관을 막음으로써 시린 이 증상이 재발하는 것을 효과적으로 방지할 수 있다. Unlike Patent Document 1, which forms a thin film on the surface of dentin and induces remineralization (remineralization) by including peptides and tricalcium phosphate, the oral composition according to the present invention, the paste-type plug compound directly penetrates into the dentinal tubules to form a plug It is characterized by blocking by forming. In the present invention, even though a separate phosphoric acid component is not included, calcium ions and phosphate ions already contained in saliva (saliva) and fluid in the dentinal tubule react with the paste-type plug compound to be mineralized to form a plug (stopper). There is a difference. Since this forms a plug chemically similar to the user's dentin and dentinal tubules, it is possible to effectively prevent the recurrence of cold lice symptoms by more firmly blocking the dentinal tubules.
펩타이드의 형태로 첨가되는 경우, 펩타이드 구조자체가 워낙 안정적이기 때문에 여기서 아미노산을 분리/분해하려면 추가적으로 가수분해(hydrolysis) 과정이 일어나야 한다. 따라서 본원발명과 같은 페이스트형 플러그 화합물(Glutamine Bicarbonate)의 생성이 어렵고, 이에 따라 탄산칼슘의 하이드록시아파타이트(Ca10(PO4)6(OH)2) 변형 또한 어려워진다. When added in the form of a peptide, since the peptide structure itself is so stable, an additional hydrolysis process must occur to separate/decompose amino acids therein. Therefore, it is difficult to produce a paste-type plug compound (Glutamine Bicarbonate) as in the present invention, and accordingly, hydroxyapatite (Ca 10 (PO 4 ) 6 (OH) 2 ) transformation of calcium carbonate also becomes difficult.
따라서 단독의 아미노산이 접착 특성을 갖는 페이스트형 플러그를 만드는데 유리하고(1차 봉쇄), 더 빠르고 손쉽게 페이스트형 플러그 화합물(Glutamine Bicarbonate)을 생성하고 이는 탄산칼슘이 더욱 견고한 하이드록시아파타이트로 변형되는데 유리한 조건을 만들어 준다.Therefore, a single amino acid is advantageous for making a paste-like plug with adhesive properties (primary blockade), and produces a paste-like plug compound (Glutamine Bicarbonate) more quickly and easily, which is an advantageous condition for transforming calcium carbonate into more durable hydroxyapatite makes
상기 구강용 조성물은 치약 조성물일 수 있으나 이에 제한되지 않는다. 더욱 현저한 시린이 증상 완화 효과를 위하여 상기 기능성 성분을 포함하는 가글액이나 치과에서 스케일링 후에 쓰는 폴리싱 페이스트(Polishing paste)를 병행하여 사용할 수 있다. 예를 들어, 치약 조성물인 경우 상기 기능성 성분 이외에 습윤제(예를 들어, 물, 벤질알코올, 소르비톨, 사카린, 수크랄로스, 글리세린, 프로필렌글리콜 또는 이들의 혼합물), 점도조절제(예를 들어, 잔탄검, 카르복시메틸셀룰로오스, 카라기난, 카르복시비닐폴리머, 알긴산 나트륨, 8μm 이하 실리카 또는 이들의 혼합물), 계면활성제(예를 들어, 코카미도프로필베타인, 폴리에틸렌글리콜, 플록사머, 라우릴황산나트륨 또는 이들의 혼합물), 불소제(플루오르화나트륨, 플루오르화아민, 일불소인산나트륨), pH조절제(예를 들어, 수산화나트륨, 수산화칼륨, 인산나트륨, 인산이나트륨, 인산삼나트륨, 피로인산나트륨, 구연산나트륨), 방부제(예를 들어, 산화아연, 산화티탄, 구연산, 호박산, 파라벤, 주석산, 파라옥시안식향산에틸파라벤, 나트로틱스 또는 이들의 혼합물) 및 향미제(예를 들어, 사카린, 아스파탐, 감초산, 페퍼민트오일, 멘톨, 카르본, 스페아민트오일 또는 이들의 혼합물)로 구성되는 군에서 선택되는 1종 이상을 더 포함한다.The oral composition may be a toothpaste composition, but is not limited thereto. A gargling liquid containing the functional ingredient or a polishing paste used after scaling in a dental office can be used in parallel for a more pronounced symptom relief effect. For example, in the case of a toothpaste composition, in addition to the functional component, a humectant (eg, water, benzyl alcohol, sorbitol, saccharin, sucralose, glycerin, propylene glycol or a mixture thereof), a viscosity modifier (eg, xanthan gum, carboxylate) Methyl cellulose, carrageenan, carboxyvinyl polymer, sodium alginate, silica of 8 μm or less or mixtures thereof), surfactants (eg, cocamidopropyl betaine, polyethylene glycol, phloxamer, sodium lauryl sulfate or mixtures thereof), fluorine agent (sodium fluoride, fluorinated amine, sodium monofluorophosphate), pH adjusting agent (e.g., sodium hydroxide, potassium hydroxide, sodium phosphate, disodium phosphate, trisodium phosphate, sodium pyrophosphate, sodium citrate), preservative ( For example, zinc oxide, titanium oxide, citric acid, succinic acid, parabens, tartaric acid, ethylparaben parahydroxybenzoate, natrotics or mixtures thereof) and flavoring agents (eg saccharin, aspartame, licorice acid, peppermint oil, Menthol, carbon, spearmint oil, or a mixture thereof) further includes at least one selected from the group consisting of.
<실시예 및 비교예><Examples and Comparative Examples>
글루타민(glutamine)을 5wt%, 10wt% 포함하는 치약 조성물(실시예 1-2), 글루타민(glutamine)을 1wt%, 3wt% 포함하는 치약 조성물(비교예 1-2), 실리카 기반 불소화물(silica-based fluoride)을 포함(불소 1450 ppm)하는 치약 조성물(비교예 3), 질산칼륨(potassium nitrate)을 5wt% 포함하는 치약 조성물(비교예 4)을 제조하였다. 상기 치약 조성물은 상기 조성을 제외한 나머지 성분으로 습윤제, 연마제, 점도조절제, 계면활성제, 방부제 및 착향제를 동일한 비율로 첨가하였다. A toothpaste composition containing 5wt% and 10wt% of glutamine (Example 1-2), a toothpaste composition containing 1wt% and 3wt% of glutamine (Comparative Example 1-2), a silica-based fluoride (silica -based fluoride) containing (fluorine 1450 ppm) (Comparative Example 3), a toothpaste composition (Comparative Example 4) containing 5wt% of potassium nitrate (potassium nitrate) was prepared. The toothpaste composition was added with the same ratio of a wetting agent, an abrasive, a viscosity modifier, a surfactant, a preservative and a flavoring agent as the remaining ingredients except for the above composition.
불소 포함 치약 조성물은 시린 이 증상 완화 효과가 없는 일반적인 치약으로서 비교예로 제조(비교예 3)하여 실시예에 따른 치약 조성물의 시린 이 증상 완화 효과 존재 여부를 확인하였다. The fluorine-containing toothpaste composition was prepared as a comparative example (Comparative Example 3) as a general toothpaste having no effect of alleviating the symptoms of toothache, and it was confirmed whether or not the toothpaste composition according to the example had an effect of alleviating the symptoms of toothache.
또한 일반적으로 차가운걸 먹을때 이가 시린 이유는 치수내 신경이 자극되어서 인데, 이론상으론 이때 칼륨(potassium) 이온이 활동전위(action potential)가 발현되는 역치(threshold)를 높여준다고 알려져 있어 비교예로 제조(비교예 4)하여 시린 이 증상 완화 효과의 현저성을 비교하였다.In addition, the reason why teeth ache when eating cold food in general is that the nerves in the pulp are stimulated. (Comparative Example 4) to compare the significance of the effect of alleviating the symptoms of ache.
또한 본 발명에서 제시한 범위를 벗어나 글루타민을 포함하는 경우를 비교예로 제조(비교예 1-2)하여 글루타민 함량을 제한한 임계적 의의를 확인하였다. In addition, the critical significance of limiting the glutamine content was confirmed by preparing a comparative example (Comparative Example 1-2) in which glutamine was included outside the range suggested in the present invention.
상기 치약 조성물의 조성은 하기 표 1에 나타내었다. 습윤제 1은 글리세린 및 물을 포함(글리세린:물=1.3:1)하고, 습윤제 2는 소르비톨 및 프로필렌글리콜을 포함하며, 점도조절제는 CMC, 실리카 및 잔탄검을 포함하고, 불소제는 일불소인산나트륨을 포함하며, 계면활성제는 PEG-60 하이드로제네이티드캐스터오일(PEG-60 Hydrogenated castor oil)을 포함하고, pH 조절제는 수산화나트륨 및 인산나트륨을 포함하며, 방부제는 이산화티타늄 및 파라벤을 포함하고, 향미제는 착향제 및 사카린을 포함하며, 각 제제 성분들의 혼합비율은 모두 동일하게 제조되었다. The composition of the dentifrice composition is shown in Table 1 below. Wetting agent 1 contains glycerin and water (glycerin: water = 1.3: 1), wetting agent 2 contains sorbitol and propylene glycol, viscosity modifier contains CMC, silica and xanthan gum, and fluorine contains sodium monofluorophosphate The surfactant includes PEG-60 hydrogenated castor oil, the pH adjusting agent includes sodium hydroxide and sodium phosphate, the preservative includes titanium dioxide and parabens, and the flavoring agent contains a flavoring agent and saccharin, and the mixing ratio of each formulation component was prepared in the same way.
성분Functional
ingredient
<실험예><Experimental example>
(1) 전자현미경 측정(1) Electron microscope measurement
먼저 상아질 시편을 제조하고 (dentine slice) 상아세관이 열리도록 6% citric acid에 담궜다가 초음파 세척기로 세척하였다. 구강환경과 비슷한 상황을 만들기 위해 하트맨 용액 Hartmann's solution [sodium chloride (6 g, 102.6 mmol), sodium lactate (3.12 g, 27.8 mmol), potassium chloride (0.4 g, 5.3 mmol) calcium chloride (0.27 g, 2.4 mmol) in water (1000 mL)]에 2분간 담근 후 인공타액 용액으로 세정하였다.First, dentine specimens were prepared (dentine slices), soaked in 6% citric acid to open dentinal tubules, and washed with an ultrasonic cleaner. Hartmann's solution [sodium chloride (6 g, 102.6 mmol), sodium lactate (3.12 g, 27.8 mmol), potassium chloride (0.4 g, 5.3 mmol) calcium chloride (0.27 g, 2.4 mmol) in water (1000 mL)] for 2 minutes and washed with artificial saliva solution.
상아질 시편에 실시예 1 및 비교예 3의 치약 조성물로 30분간 처리(상아질 시편에 인공타액을 바른 후 인공타액 및 치약 조성물을 2:1로 섞은 슬러리(slurry)를 사용하여 30분간 셰이커(Shaker)를 사용)하고 흐르는 증류수(deionised water)에 세척하고 상온에서 건조후에 전자현미경(약 2000배)으로 관찰하였다. Treatment of dentin specimens with the toothpaste composition of Example 1 and Comparative Example 3 for 30 minutes (after applying artificial saliva to the dentin specimen, shaker for 30 minutes using a slurry mixed with artificial saliva and toothpaste composition in a ratio of 2: 1) After washing with flowing distilled water (deionised water) and drying at room temperature, it was observed with an electron microscope (approximately 2000 times).
도 4에 실시예 및 비교예에 따른 치약 조성물 처리 후 전자현미경 이미지를 나타내었다. 도 4에 나타난 것과 같이 5%~10% 글루타민 포함하는 치약 조성물을 처리한 실시예의 경우 상아세관이 폐쇄된 것을 확인할 수 있으며, 종래의 시린이 기능성 치약(비교예 4)과 비교하더라도 우수한 상아세관 폐쇄 효과를 갖는 것을 알 수 있다. 4 shows an electron microscope image after treatment with the dentifrice composition according to Examples and Comparative Examples. As shown in Figure 4, in the case of the example treated with a toothpaste composition containing 5% to 10% glutamine, it can be confirmed that the dentinal tubules are closed, and excellent dentinal tubule closure even when compared to the conventional shirin functional toothpaste (Comparative Example 4) It can be seen that it has an effect.
실시예 2(10% glutamine)의 경우 실시예 1(5% glutamine)과 거의 동일한 상아세관 봉쇄(dentinal tubule occlusion)가 이루어진 것을 확인할 수 있으므로 10%를 초과하여 글루타민을 포함할 필요가 없는 것으로 판단되며, 10% 초과하는 조성으로는 배합이 어렵고, 5% 미만(1% ~ 3%) 글루타민을 포함하는 비교예 1-2의 경우 상아세관 봉쇄(dentinal tubule occlusion)가 제대로 이루어 지지 않으므로, 5%~10% 글루타민을 포함하는 것이 최적임을 확인하였다.In the case of Example 2 (10% glutamine), it can be confirmed that dentinal tubule occlusion is almost the same as that of Example 1 (5% glutamine), so it is judged that there is no need to include glutamine in excess of 10% , It is difficult to mix with a composition exceeding 10%, and in the case of Comparative Example 1-2 containing less than 5% (1% to 3%) glutamine, dentinal tubule occlusion is not properly achieved, so 5% to Inclusion of 10% glutamine was found to be optimal.
(2) 임상적 설문평가(participant survey)(2) Clinical survey (participant survey)
60명의 시린이 증상을 호소하는 자원자를 대상으로 10명씩 6그룹으로 나누어서 실시예 1(5% glutamine), 비교예 3 (불소 1450 ppm) 및 비교예 4(5% potassium nitrate)을 치약 대용으로 하루 2번 2분간 사용하도록 하였다. 2주일간 사용 후 5점 리커트 스케일 (Likert scale)로 설문 평가를 하였다. 그 결과를 하기 표 2에 나타내었다. 60 volunteers who complained of symptoms were divided into 6 groups of 10 each, and Example 1 (5% glutamine), Comparative Example 3 (Fluoride 1450 ppm), and Comparative Example 4 (5% potassium nitrate) were used as substitutes for toothpaste for a day. It was used twice for 2 minutes. After using it for 2 weeks, a questionnaire was evaluated on a 5-point Likert scale. The results are shown in Table 2 below.
* 리커트 스케일: 새로운 치약 사용 후 시린이 증상이 완화되었다.* Likert scale: After using the new toothpaste, the symptoms of numbness were alleviated.
1: Strongly disagree (전혀 그렇지 않다)1: Strongly disagree
2: Disagree (그렇지 않다)2: Disagree (disagree)
3: Nether agree nor disagree (모르겠다)3: Nether agree nor disagree
4: Agree (그렇다)4: Agree
5: Strongly agree (굉장히 그렇다)5: Strongly agree
상기 표 2에 나타난 것과 같이 글루타민, 탄산수소나트륨 및 탄산칼슘을 포함하는 기능성 성분은 22.5 내지 35 중량% 포함하고, 글루타민 : 탄산수소나트륨 : 탄산칼슘의 혼합 비율은 1 : 1.5~2 : 1~1.5 인 실시예 1-2의 시린이 증상이 완화 효과가 비교예 1-4에 비하여 매우 우수한 것을 알 수 있으며, 특히 기능성 성분은 30 내지 35 중량% 포함하고, 글루타민 : 탄산수소나트륨 : 탄산칼슘의 혼합 비율이 1 : 1.5~1.8 : 1~1.2 인 실시예 2의 시린이 증상 완화 효과가 가장 우수한 것을 확인할 수 있다. As shown in Table 2, the functional ingredients including glutamine, sodium bicarbonate and calcium carbonate are included in an amount of 22.5 to 35% by weight, and the mixing ratio of glutamine: sodium bicarbonate: calcium carbonate is 1: 1.5-2: 1-1.5 It can be seen that the effect of alleviating the symptoms of a cold sore in Example 1-2 is very excellent compared to Comparative Example 1-4, and in particular, the functional component contains 30 to 35% by weight, and a mixture of glutamine: sodium bicarbonate: calcium carbonate It can be seen that the ratio of 1: 1.5 to 1.8: 1 to 1.2 in Example 2 is the most excellent symptom alleviation effect.
전술한 각 실시예에서 예시된 특징, 구조, 효과 등은 실시예들이 속하는 분야의 통상의 지식을 가지는 자에 의하여 다른 실시예들에 대해서도 조합 또는 변형되어 실시 가능하다. 따라서 이러한 조합과 변형에 관계된 내용들은 본 발명의 범위에 포함되는 것으로 해석되어야 할 것이다.The features, structures, effects, etc. illustrated in each of the above-described embodiments can be combined or modified with respect to other embodiments by those skilled in the art in the field to which the embodiments belong. Therefore, contents related to these combinations and variations should be construed as being included in the scope of the present invention.
Claims (5)
상기 기능성 성분 내에서 글루타민 : 탄산수소나트륨 : 탄산칼슘의 혼합 중량 비율은 1 : 1.5~2 : 1~1.5 인 것을 특징으로 하는 구강용 조성물.
Contains functional ingredients that form a paste-type plug compound, including glutamine, sodium hydrogen carbonate and calcium carbonate;
The oral composition, characterized in that the mixing weight ratio of glutamine: sodium bicarbonate: calcium carbonate in the functional component is 1: 1.5 ~ 2: 1 ~ 1.5.
상기 기능성 성분은 22.5 내지 35 중량% 포함되는 것을 특징으로 하는 구강용 조성물.
According to claim 1,
Oral composition, characterized in that the functional component is contained in 22.5 to 35% by weight.
상기 구강용 조성물은 습윤제, 점도조절제, 계면활성제, 불소제, pH 조절제, 방부제 및 향미제로 구성되는 군에서 선택되는 1종 이상을 더 포함하는 치약 조성물인 것을 특징으로 하는 구강용 조성물.According to claim 1,
The oral composition is characterized in that the toothpaste composition further comprises at least one member selected from the group consisting of a wetting agent, a viscosity modifier, a surfactant, a fluorine agent, a pH adjusting agent, a preservative and a flavoring agent Oral composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220083734A KR102474196B1 (en) | 2022-07-07 | 2022-07-07 | Functional oral composition containing glutamine to relieve dentin hypersensitivity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220083734A KR102474196B1 (en) | 2022-07-07 | 2022-07-07 | Functional oral composition containing glutamine to relieve dentin hypersensitivity |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102474196B1 true KR102474196B1 (en) | 2022-12-06 |
Family
ID=84407376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220083734A KR102474196B1 (en) | 2022-07-07 | 2022-07-07 | Functional oral composition containing glutamine to relieve dentin hypersensitivity |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102474196B1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101956579B1 (en) | 2018-05-09 | 2019-03-11 | 주식회사 하이센스바이오 | Toothpaste composition for alleviating dentine hyperesthesia |
US20210093534A1 (en) * | 2019-09-30 | 2021-04-01 | The Procter & Gamble Company | Dentifrice compositions comprising bicarbonate salt and neutral amino acid |
-
2022
- 2022-07-07 KR KR1020220083734A patent/KR102474196B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101956579B1 (en) | 2018-05-09 | 2019-03-11 | 주식회사 하이센스바이오 | Toothpaste composition for alleviating dentine hyperesthesia |
US20210093534A1 (en) * | 2019-09-30 | 2021-04-01 | The Procter & Gamble Company | Dentifrice compositions comprising bicarbonate salt and neutral amino acid |
Non-Patent Citations (8)
Title |
---|
1. West N X, Sanz M, Lussi A, Bartlett D, Bouchard P and Bourgeois D (2013). Prevalence of dentine hypersensitivity and study of associated factors: a European population-based cross-sectional study. J Dent. 41(10): 841-851. |
2. Gysi A (1900). An attempt to explain the sensitiveness of dentine. Brit J Dental Sci. 43: 865-868. |
3. Brㅴnnstrㆆm M (1963)a. A hydrodynamic mechanism in the transmission of pain producing stimuli through the dentine. In: Sensory mechanisms in dentine, ed. D. J. Anderson. Oxford: Pergamon Press, pp. 73??9. |
4. Brㅴnnstrㆆm M (1965). The surface of sensitive dentine. An experimental study using replication. Odontol Revy. 16(4): 293-299. |
5. Brㅴnnstrㆆm M (1966). Sensitivity of dentine. Oral Surg Oral Med Oral Pathol. 21(4): 517-526. |
6. Absi E G, Addy M and Adams D (1987). Dentine hypersensitivity. A study of the patency of dentinal tubules in sensitive and non-sensitive cervical dentine. J Clin Periodontol. 14(5): 280-284. |
7. Narhi M, Jyvasjarvi E, Virtanen A, Huopaniemi T, Ngassapa D and Hirvonen T (1992). Role of intradental A- and C-type nerve fibres in dental pain mechanisms. Proc Finn Dent Soc. 88 Suppl 1: 507-516. |
8. West N X, Seong J and Davies M (2015)c. Management of dentine hypersensitivity: efficacy of professionally and self-administered agents. J Clin Periodontol. vol 42 Suppl 16., pp. S256-302. |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6101712B2 (en) | Multi-component oral care composition | |
JP5816549B2 (en) | Compositions and methods for improving fluoride uptake using bioactive glass | |
CN107809997B (en) | Oral care compositions | |
EP3648731B1 (en) | Oral care composition | |
WO2005004824A1 (en) | Oral cavity composition | |
JPH1017449A (en) | Composition for hyperesthesia | |
KR101569348B1 (en) | Oral composition for sensitive teeth | |
CN110769801A (en) | Oral care compositions | |
CN109431834B (en) | Oral composition added with bioactive glass and strontium chloride and application thereof | |
KR102474196B1 (en) | Functional oral composition containing glutamine to relieve dentin hypersensitivity | |
KR102474214B1 (en) | Functional oral composition containing arginine to relieve dentin hypersensitivity | |
CN110545784B (en) | Oral care compositions | |
EP3554459B1 (en) | Oral care composition | |
JP6038567B2 (en) | Oral composition | |
EP3500232B1 (en) | Oral care composition | |
JP4542843B2 (en) | Oral composition | |
CN109152935B (en) | Oral care compositions | |
WO2007065856A1 (en) | Oral compositions comprising rod-shaped apatite nanocrystals | |
KR100704585B1 (en) | Toothpaste composition | |
KR101583758B1 (en) | Toothpaste composition comprising kiyoseki stone | |
JP3820402B2 (en) | Oral composition and gum | |
JPH05155745A (en) | Composition for oral cavity | |
CN110691581B (en) | Dentifrice composition | |
EP3903764A1 (en) | Multipurpose fluorinated biphosphate toothpaste composition | |
EP2956112B1 (en) | Dental composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |